8-K: Harrow Reports Strong Q3 2025 Revenue Growth, Updates Outlook

Harrow, Inc. announced a 45% increase in Q3 2025 revenues to $71.6 million, driven by strong performance from VEVYE and IHEEZO, while adjusting full-year guidance due to underperforming products and an inventory shortage.

Summary

• Total revenues for Q3 2025 reached $71.6 million, a 45% increase compared to $49.3 million in the prior-year period.
• GAAP net income for Q3 2025 was $1.0 million, a significant improvement from a GAAP net loss of $(4.2) million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $22.7 million, up from $8.8 million in the prior-year period.
• Cash and cash equivalents stood at $74.3 million as of September 30, 2025.
• VEVYE revenue increased 22% quarter-over-quarter to $22.6 million in Q3 2025, achieving a 10.5% share of the national dry eye disease market.
• IHEEZO revenue increased 20% sequentially to $21.9 million in Q3 2025, representing a 70% increase from Q3 2024.
• The company updated its full-year revenue outlook to a range of $270 million to $280 million, a slight reduction from previous guidance.
• Harrow successfully completed a refinancing in September 2025, reducing annual interest expenses by approximately $3 million and adding $50 million in new liquidity.
• The acquisition of Melt Pharmaceuticals, Inc. is progressing, with its lead candidate MELT-300 anticipated for NDA submission in H1 2027 and potential commercial launch in 2028.
• TRIESENCE and the Rare & Specialty Products (RSP) portfolio underperformed expectations in Q3 2025, but management anticipates a turnaround with new leadership and the HAFA program.

Sentiment

Score: 7

Explanation: The sentiment is generally positive due to strong revenue growth, significant improvement in GAAP net income and Adjusted EBITDA, and the robust performance of key products like VEVYE and IHEEZO. Strategic acquisitions and refinancing also contribute positively. However, underperformance in certain product lines and a slight reduction in full-year guidance temper the overall sentiment, indicating some areas requiring focused attention.

Positives

• Total revenues increased by 45% year-over-year to $71.6 million in Q3 2025, demonstrating strong top-line growth.
• Achieved GAAP net income of $1.0 million in Q3 2025, a significant turnaround from a net loss in the prior year.
• Adjusted EBITDA surged to $22.7 million in Q3 2025, indicating improved operational efficiency and profitability.
• VEVYE revenue grew 22% quarter-over-quarter to $22.6 million and captured 10.5% of the national dry eye disease market share by quarter-end, with new preferred formulary listings effective January 1, 2026.
• IHEEZO revenue increased 20% sequentially to $21.9 million, tracking towards a record year and exceeding full-year revenue targets.
• Successfully completed a refinancing in September 2025, reducing annual interest expense by approximately $3 million, extending debt maturities, and adding $50 million in new liquidity.
• The acquisition of Melt Pharmaceuticals, Inc. and its lead candidate MELT-300 represents a transformative long-term growth opportunity in non-opioid procedural sedation.
• Launched Harrow Access for All (HAFA) program, expanding patient-centric access across the entire portfolio, building on the success of VEVYE Access For All (VAFA).
• Strengthened commercial leadership team with several key hires, including Patrick Sullivan (Head of Commercial) and Tom Curatolo (VP, Rare & Specialty Portfolio).
• Cash and cash equivalents increased to $74.3 million as of September 30, 2025, from $47.2 million at December 31, 2024.

Negatives

• TRIESENCE and the Rare & Specialty Products (RSP) portfolio underperformed expectations in Q3 2025.
• ImprimisRx experienced an inventory shortage in October 2025, which will likely not be made up this year, contributing to a reduction in overall full-year guidance.
• GAAP net loss for the nine months ended September 30, 2025, was $(11.8) million, despite a profitable third quarter.
• GAAP gross margin slightly decreased to 75% in Q3 2025 from 76% in Q3 2024.
• VEVYE's net price per unit (NPP) experienced a modest sequential decline, though it is expected to firm in the near term.

Risks

• Risks related to liquidity or results of operations.
• Ability to successfully implement the business plan, develop and commercialize products, product candidates, and proprietary formulations in a timely manner or at all.
• Ability to identify and acquire additional products, manage pharmacy operations, refinance and service debt, and obtain necessary financing.
• Challenges in recruiting and retaining qualified personnel and managing any growth experienced.
• Competition from pharmaceutical companies, outsourcing facilities, and pharmacies.
• General economic and business conditions, including inflation and supply chain challenges.
• Regulatory and legal risks and uncertainties related to pharmacy operations and the pharmaceutical business, including ongoing communications with the U.S. Food and Drug Administration regarding compliance and quality plans.
• Physician interest in and market acceptance of current and future formulations and compounding pharmacies generally.

Future Outlook

Harrow anticipates a strong finish to 2025, with VEVYE and IHEEZO expected to achieve record fourth quarters and meet or exceed full-year revenue targets. The company plans to launch BYQLOVI in early 2026, BYOOVIZ in mid-2026, and OPUVIZ in mid-2027, positioning itself uniquely in the retinal space. Management expects a meaningful rebound for TRIESENCE and the Rare & Specialty Portfolio in Q4 2025 and into 2026. The NDA submission for MELT-300 is targeted for the first half of 2027, with a potential commercial launch in 2028, though efforts are underway to accelerate this timeline. The full-year revenue outlook for 2025 has been slightly reduced to $270 million to $280 million.

Management Comments

• "The third quarter represented another period of meaningful progress for Harrow. We continued to execute across our portfolio, driving strong performance from VEVYE and IHEEZO, while advancing several strategic initiatives that strengthen our foundation for future growth."
• "With the launch of TRIESENCE into its largest market opportunity, the upcoming rollout of our Harrow Access for All (HAFA) program, the expansion of our commercial leadership team, and new major coverage wins for VEVYE, we are well-positioned for a terrific close to the year and sustained growth for many years to come."
• "I am encouraged by the continued strong momentum we’re seeing with VEVYE and IHEEZO. Both products are on track for a record year, performing above expectations and steadily gaining market share."
• "TRIESENCE and our Rare & Specialty Products (RSP) portfolio have not met my expectations this year – including in the third quarter. Its way too early to despair about TRIESENCE... I strongly believe we are on the right track with TRIESENCE."
• "I take responsibility for the fact that we have not allocated the right resources to this part of our business, and I recognize that over the past few quarters, we have not met the mark. I, too, am tired of excuses, and we are taking action."
• "The pending acquisition of MELT Pharmaceuticals and its lead candidate, MELT-300, represents a transformational long-term growth opportunity for Harrow."
• "Our goal is to operate with gross leverage of under 3x and net leverage of under 2x, and we expect to achieve these levels in the near term as we execute our growth plans."
• "I am confident that we have the right strategies, leadership, and commercial infrastructure in place to position Harrow for sustained growth and margin expansion."

Industry Context

Harrow operates in the North American ophthalmic disease management solutions market, which includes treatments for conditions like dry eye disease, cataracts, and retinal diseases. The company's focus on expanding patient access programs (VAFA, HAFA) and developing non-opioid sedation alternatives (MELT-300) aligns with broader industry trends towards patient-centric care, cost-effectiveness, and addressing the opioid crisis. The strong performance of VEVYE and IHEEZO indicates successful penetration in competitive segments, while the challenges with TRIESENCE and the RSP portfolio highlight the dynamic nature of product adoption and market resource allocation within the pharmaceutical industry.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential for sustained growth and long-term value creation through strong product performance, strategic acquisitions, and improved financial flexibility, despite some near-term challenges.
• Patients: Expanded access and affordability to ophthalmic medications through HAFA and VAFA programs, and potential for safer, non-opioid sedation options with MELT-300.
• Physicians/Eye Care Professionals: Access to a comprehensive suite of therapies for ocular surface disease, dry eye, and retinal conditions, with differentiated clinical and operational value from products like VEVYE and IHEEZO.
• Employees: Strengthening of the commercial leadership team and continued investment in commercial infrastructure, potentially leading to new opportunities and roles.

Next Steps

• Rollout of the Harrow Access for All (HAFA) program this quarter.
• Expansion of VEVYE commercial infrastructure, including opening 10 new territories and more in the first half of 2026.
• Upcoming launch of BYQLOVI in early 2026.
• Introduction of BYOOVIZ in mid-2026 and OPUVIZ in mid-2027.
• Accelerate the development of MELT-300, including initiating one non-clinical animal study and three pharmacokinetic (PK) studies.
• Prepare for New Drug Application (NDA) submission for MELT-300 in the first half of 2027.
• Enhance marketing capabilities by the end of the year.
• Provide additional commentary on Q4 2025 results, including the expected magnitude of impact from fourth-quarter stocking activity, when full-year 2025 results are reported.

Key Dates

Recommendation

Harrow's Q3 2025 results demonstrate robust revenue growth and a return to GAAP net income, driven by the strong performance of flagship products VEVYE and IHEEZO, which are gaining significant market share and securing new payer coverage. Strategic initiatives, including the Melt acquisition and the expansion of patient access programs, position the company for long-term growth. The successful refinancing also improved financial flexibility. However, the underperformance of TRIESENCE and the Rare & Specialty Products portfolio, coupled with an inventory shortage at ImprimisRx leading to a slight reduction in full-year revenue guidance, introduces some near-term execution risks and uncertainty. While the long-term outlook is promising, a 'hold' recommendation is appropriate until there is more consistent performance across the entire product portfolio and clarity on the impact of the revised guidance.

Keywords

Ophthalmic, Dry Eye Disease, VEVYE, IHEEZO, TRIESENCE, Melt Pharmaceuticals, MELT-300, ImprimisRx, Q3 2025 Financial Results, Pharmaceutical, Biotechnology, SEC Filing, HROW, Corporate Governance, Risk Management